Abstract
The aim of the present study was to compare the efficacy of a novel phosphodiesterase 4 and 5 inhibitor, LASSBio596, with that of dexamethasone in a murine model of chronic asthma. Lung mechanics (airway resistance, viscoelastic pressure, and static elastance), histology, and airway and lung parenchyma remodeling (quantitative analysis of collagen and elastic fiber) were analyzed. Thirty-three BALB/c mice were randomly assigned to four groups. In the asthma group (N = 9), mice were immunized with 10 microg ovalbumin (OVA, ip) on 7 alternate days, and after day 40 they were challenged with three intratracheal instillations of 20 microg OVA at 3-day intervals. Control mice (N = 8) received saline under the same protocol. In the dexamethasone (N = 8) and LASSBio596 (N = 8) groups, the animals of the asthma group were treated with 1 mg/kg dexamethasone disodium phosphate (0.1 mL, ip) or 10 mg/kg LASSBio596 dissolved in dimethyl sulfoxide (0.2 mL, ip) 24 h before the first intratracheal instillation of OVA, for 8 days. Airway resistance, viscoelastic pressure and static elastance increased significantly in the asthma group (77, 56, and 76%, respectively) compared to the control group. The asthma group presented more intense alveolar collapse, bronchoconstriction, and eosinophil and neutrophil infiltration than the control group. Both LASSBio596 and dexamethasone inhibited the changes in lung mechanics, tissue cellularity, bronchoconstriction, as well as airway and lung parenchyma remodeling. In conclusion, LASSBio596 at a dose of 10 mg/kg effectively prevented lung mechanical and morphometrical changes and had the potential to block fibroproliferation in a BALB/c mouse model of asthma.
Highlights
The SigmaStat 2.0 statistical software package (Jandel Scientific Corporation, San Raphael, CA, USA) was used
Phosphodiesterase 4 (PDE4) inhibitors could be effective therapeutic options for asthma [3] because they increase intracellular concentrations of cyclic AMP, which has a broad range of antiinflammatory and anti-fibrotic effects on various key effector cells involved in asthma [3,4]
The present study was undertaken to test the effects of LASSBio596 on respiratory mechanics, lung morphometry, and airway and lung parenchyma remodeling in a murine model of chronic asthma
Summary
The SigmaStat 2.0 statistical software package (Jandel Scientific Corporation, San Raphael, CA, USA) was used. The present study was undertaken to test the effects of LASSBio596 on respiratory mechanics, lung morphometry, and airway and lung parenchyma remodeling in a murine model of chronic asthma. For the dexamethasone and LASSBio596 groups (N = 8 each) the animals were sensitized and challenged as in the asthma group and treated for 8 consecutive days with ip injections of dexamethasone and LASSBio596, respectively, starting 24 h before the first intratracheal challenge with OVA.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Brazilian Journal of Medical and Biological Research
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
